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Polyhalogenated aromatic hydrocarbons (PHAHs), such as
polychlorinated dibenzo-p-dioxins and dibenzofurans, poly-
brominated diphenylethers, and bisphenol A derivatives are
persistent environmental pollutants, which are capable of in-
terfering with reproductive and endocrine function in birds,
fish, reptiles, and mammals. PHAHs exert estrogenic effects
that may be mediated in part by their hydroxylated metabo-
lites (PHAH-OHs), the mechanisms of which remain to be iden-
tified. PHAH-OHs show low affinity for the ER. Alternatively,
they may exert their estrogenic effects by inhibiting E2 me-
tabolism. As sulfation of E2 by estrogen sulfotransferase
(SULT1E1) is an important pathway for E2 inactivation, in-
hibition of SULT1E1 may lead to an increased bioavailability
of estrogens in tissues expressing this enzyme. Therefore, we
studied the possible inhibition of human SULT1E1 by hy-
droxylated PHAH metabolites and the sulfation of the differ-
ent compounds by SULT1E1. We found marked inhibition of
SULT1E1 by various PHAH-OHs, in particular by compounds
with two adjacent halogen substituents around the hydroxyl
group that were effective at (sub)nanomolar concentrations.
Depending on the structure, the inhibition is primarily com-
petitive or noncompetitive. Most PHAH-OHs are also sulfated
by SULT1E1. We also investigated the inhibitory effects of the
various PHAH-OHs on E2 sulfation by human liver cytosol and
found that the effects were strongly correlated with their in-
hibitions of recombinant SULT1E1 (r 0.922). Based on these
results, we hypothesize that hydroxylated PHAHs exert their
estrogenic effects at least in part by inhibiting SULT1E1-
catalyzed E2 sulfation. (J Clin Endocrinol Metab 87: 1142–1150,
2002)
RECENTLY, MANY STUDIES have been performed onthe interaction of environmental chemicals with the
endocrine system, which results in reproductive and devel-
opmental anomalies in various organisms (1–4). Endocrine-
disrupting effects have been observed in adult animals that
were exposed in utero to polyhalogenated aromatic hydro-
carbons (PHAHs) such as polychlorinated dibenzo-p-dioxins
(PCDDs), polychlorinated dibenzofurans (PCDFs), and poly-
chlorinated biphenyls (PCBs) (5–7). Hilakivi-Clarke et al. (8)
demonstrated in rats that exposure to natural estrogens in
utero advanced puberty onset and increased breast cancer
risk in the offspring; this may also apply to environmental
estrogens. In humans, abnormalities in the development of
the reproductive tract, reduced sperm counts (3, 9), and
increased incidence of germ cell cancer (10) have been related
to exposure to endocrine disrupters present in the environ-
ment. Furthermore, several studies have reported increased
levels of PCBs, 2,2-bis-(4-chlorophenyl)-1,1,1-trichloroethane
and its metabolite 2,2-bis-(4-chlorophenyl)-1,1-dichloroeth-
ylene in breast cancer patients (11, 12). However, recent
epidemiological research does not support the hypothesis
that women exposed to organochlorines such as PCBs,
PCDDs, 2,2-bis-(4-chlorophenyl)-1,1,1-trichloroethane, and
2,2-bis-(4-chlorophenyl)-1,1-dichloroethylene have an in-
creased breast cancer risk (13–15).
Hydroxylated metabolites of the PHAHs (PHAH-OHs)
may contribute to the aforementioned effects. Hydroxylated
metabolites of PCBs (PCB-OHs), PCDDs (PCDD-OHs), and
PCDFs (PCDF-OHs) and other organohalogens have been
identified in blood, bile, and urine of animals treated with the
parent compound, but also in wildlife samples as well as in
environmentally exposed human subjects (16–20). Hydroxy-
lation of PCDDs and PCDFs in mammals preferentially oc-
curs on the lateral (2, 3, 7, 8) positions (18–20). For PCBs, it
has been determined that hydroxylated metabolites are par-
tially responsible for the endocrine-disrupting effects. For
instance, Crews et al. (21) showed that different hydroxylated
PCBs altered the sexual differentiation of the turtle.
Abbreviations: BPA, Bisphenol A; -OH, hydroxylated metabolite of;
PAPS, 3-phosphoadenosine-5-phosphosulfate; PBDE, polybrominated
diphenylether; PCB, polychlorinated biphenyl; PCDD, polychlorinated
dibenzo-p-dioxin; PCDF, polychlorinated dibenzofuran; PHAH, poly-
halogenated aromatic hydrocarbon; SULT1E1, estrogen sulfotrans-
ferase.
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The mechanisms by which PHAH-OHs exert their estro-
genic effects are still not understood. Binding affinities for
ER and ER are relatively low (22, 23). It is possible, how-
ever, that PHAH-OHs exert part of their estrogenic effects by
increasing the bioavailability of E2 through inhibition of E2
inactivation in target tissues. Sulfation by the specific estro-
gen sulfotransferase SULT1E1 is an important pathway for
the inactivation of E2 (24). The human enzyme has a low Km
value of 4 nm for E2 and is expressed in target tissues such
as the endometrium, mammary gland, and testis as well as
in the liver (25–29). Recently, we demonstrated potent inhi-
bition of SULT1E1 by hydroxylated PCB metabolites (30), in
particular compounds with two adjacent chlorine substitu-
ents around the hydroxyl group. Here, we have investigated
the potency and type of inhibition of human SULT1E1 by
other important PHAH-OHs, such as PCDD-OHs, PCDF-
OHs, and hydroxylated polybromodiphenylethers (PBDE-
OHs), and by halogenated bisphenol A (BPA) derivatives as
well as their sulfation by SULT1E1. To determine the rele-
vance of our findings using recombinant enzyme, we also
studied the inhibition of E2 sulfation by native SULT1E1 in
human liver cytosol (29). Furthermore, we analyzed the sul-
fation of the various PHAH-OHs by SULT1E1 and SULT1A1,
another phenol sulfotransferase abundantly expressed in hu-
man liver (31, 32).
Materials and Methods
Materials
E2 and 3-phosphoadenosine-5-phosphosulfate (PAPS) were ob-
tained from Sigma (St. Louis, MO), [3H]E2 (3.22 MBq/nmol) was ob-
tained from Amersham Pharmacia Biotech (Little Chalfont, UK), and
[35S]PAPS (52.9 MBq/mol) was purchased from NEN Life Science
Products (Boston, MA). The sources of the various hydroxylated orga-
nohalogens have been described previously (23, 33, 34). Human
SULT1E1 (35) and SULT1A1 (31) were expressed in Salmonella typhi-
murium as previously described (36, 37). Cytosolic fractions were pre-
pared and used without further purification (36, 37). SULT1E1 ac-
counted for 5–7% of the cytosolic proteins. Similar results were obtained
using recombinant SULT1E1 expressed in Escherichia coli and purified as
previously described (38). Normal human liver was obtained at surgical
resection of liver tumors, and cytosol was prepared as previously de-
scribed (39). Approval was obtained from the medical ethical committee
of Erasmus University Medical Center.
Estrogen sulfotransferase assay
Estrogen sulfotransferase activity was analyzed by measuring the
formation of water-soluble [3H]E2 sulfate after incubation of 1 nm [3H]E2
for 30 min at 37 C with recombinant SULT1E1 (0.1 g total cytosolic
protein/ml) in the presence or absence (blanks) of 50 m of the cofactor
PAPS in 0.2 ml 0.1 m sodium phosphate (pH 7.2), 2 mm EDTA, and 1 mm
dithiothreitol. The reactions were stopped by the addition of 2 ml ice-
cold water, and unreacted [3H]E2 was removed by extraction with 2 ml
dichloromethane. Sulfate formation was quantified by liquid scintilla-
tion counting of 1 ml of the aqueous phase. Enzymatic sulfation was
corrected for background radioactivity estimated in the blanks. Inhibi-
tion of E2 sulfation by PHAH-OHs was assessed by addition of 0.01 nm
to 10 m of these compounds to the reaction mixtures. Kinetic param-
eters for E2 sulfation were determined by Lineweaver-Burk analysis
(40) of the sulfation of varying substrate concentrations. Apparent Ki
values for inhibitors were calculated from the change in slope of the
Lineweaver-Burk plot in the presence of a fixed inhibitor concentra-
tion (40).
Sulfation of PHAH-OHs
The above assay of estrogen sulfotransferase activity is based on the
sulfation of limited concentrations of radioactive E2 by excess unlabeled
PAPS. As radioactive PHAH-OHs are not available, their sulfation was
analyzed in comparison with E2 by determining the transfer of 35SO3

from [35S]PAPS to an excess of unlabeled substrate. Sulfation of PHAH-
OHs by SULT1E1 was compared with their sulfation by the human
phenol sulfotransferase SULT1A1. Assay mixtures contained 1 m
PHAH-OH or E2, 0.3 m [35S]PAPS, and 15 g (recombinant SULT1E1)
or 100g (recombinant SULT1A1) of total cytosolic protein/ml in a total
volume of 150 l 10 mm potassium phosphate (pH 7.4) and were in-
cubated for 30 min at 37 C. The formation of sulfated products was
analyzed using the BaSO4 precipitation method of Foldes and Meek (41)
as well as by HPLC. In the former method, unreacted [35S]PAPS and
protein were precipitated by successive addition of 200 l 0.1 m barium
acetate, 200l 0.1 m barium hydroxide, and 200l 0.1 m zinc sulfate. The
presumably soluble sulfated products were quantified by liquid scin-
tillation counting of 500 l of the supernatant. Sulfation was corrected
for background radioactivity determined in blanks without substrate.
For HPLC analysis, the reactions were stopped by the addition of 150
l ice-cold methanol. After centrifugation, 100 l of the supernatant
were injected onto a 4.6  250-mm Symmetry C18 column connected to
an Alliance HPLC system (Waters Chromatography BV, Etten-Leur, The
Netherlands), and eluted with a gradient of acetonitrile in 50 mm triethyl
ammonium acetate (pH 6.8) at a flow of 1.0 ml/min. The proportion of
acetonitrile was increased linearly from 35% to 65% in 15 min and further
to 90% in an additional 10 min. The radioactivity in the eluate was
determined using a Radiomatic A-500 flow scintillation detector (Pack-
ard, Meriden, CT).
Results
The effects of 0.01 nm to 10 m of different classes of
PHAH-OHs on the sulfation of 1 nm E2 by SULT1E1 were
tested. Table 1 lists the exact structural formulas of the tested
compounds, and Figs. 1-4 show their core structures. The
concentration-dependent inhibition of SULT1E1 activity by
subsets of various types of PHAH-OHs is presented in Fig.
1 (PCDD-OHs), Fig. 2 (PCDF-OHs), Fig. 3 (PBDE-OHs), and
Fig. 4 (BPA derivatives). From these concentration-inhibition
curves, the concentrations causing 50% inhibition (IC50 val-
ues) were determined. Table 1 presents the IC50 values and
relative potencies compared with the cognate substrate E2
for all compounds tested.
Figure 1 shows the results with PCDD-OHs having the
hydroxyl group in position 2, and the same 7,8-dichloro
substitution pattern in the nonphenolic ring. Increasing po-
tencies were observed as the number of chlorine substituents
surrounding the hydroxyl group increased from 0 to 2, with
mean IC50 values of 300 nm for 2-OH-7,8-DiCDD, 30 nm
for 2-OH-3,7,8-TrCDD, and 4 nm for 2-OH-1,3,7,8-TeCDD
(Table 1).
Figure 2 presents the concentration-inhibition relation-
ships for PCDF-OHs with the hydroxyl group in the 2 or 3
position, para or meta to the furan oxygen, respectively.
Again, the potency increased with increasing number of
chlorine substituents adjacent to the hydroxyl group. Fur-
thermore, 3-OH-PCDFs appeared to be slightly more potent
inhibitors than 2-OH-PCDFs possessing comparable chlorine
substitution patterns. Of all the PCDF-OHs tested, 3-OH-
2,4,7,8,9-PeCDF was the most potent inhibitor of E2 sulfation.
With a mean IC50 value of as low as 0.18 nm, this compound
has a more than 30-fold higher affinity for SULT1E1 than the
natural substrate E2 (Table 1).
As demonstrated in Fig. 3, all PBDE-OHs tested were
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relatively weak inhibitors of E2 sulfation by SULT1E1, with
IC50 values greater than 200 nm (Table 1). Also, the one
hydroxylated, polychlorodiphenylether tested, 2-OH-4,2,4-
TrCDE, only inhibited SULT1E1 activity at micromolar con-
centrations (Table 1). BPA did not affect E2 sulfation at con-
centrations less than 1 m, whereas its derivatives having
halogens in all positions adjacent to the two hydroxyl groups,
TABLE 1. Potency of inhibition of human SULT1E1 activity by PHAH-OHs
Compound Code IC50 (nM)
Relative
potency
E2 3.8–7.1 1
PCDD-OH
2-Hydroxy-7,8-dichlorodibenzo-p-dioxin 2-OH-7,8-DiCDD 200–390 0.02
2-Hydroxy-3,7,8-trichlorodibenzo-p-dioxin 2-OH-3,7,8-TrCDD 28–40 0.17
2-Hydroxy-1,3,7,8-tetrachlorodibenzo-p-dioxin 2-OH-1,3,7,8-TeCDD 2.4–6.1 1.4
PCDF-OH
4-Hydroxy-1,3,6,7-tetrachlorodibenzofuran 4-OH-1,3,6,7-TeCDF 6.6–6.7 0.84
3-Hydroxy-2,6,7,8-tetrachlorodibenzofuran 3-OH-2,6,7,8-TeCDF 5.6–9.1 0.76
3-Hydroxy-2,4,7,8-tetrachlorodibenzofuran 3-OH-2,4,7,8-TeCDF 0.68–2.2 4.0
3-Hydroxy-2,4,7,8,9-pentachlorodibenzofuran 3-OH-2,4,7,8,9-PeCDF 0.16–0.20 31
2-Hydroxy-7,8-dichlorodibenzofuran 2-OH-7,8-DiCDF 230–560 0.02
2-Hydroxy-6,7,8-trichlorodibenzofuran 2-OH-6,7,8-TrCDF 350–800 0.01
2-Hydroxy-1,3,7,8-tetrachlorodibenzofuran 2-OH-1,3,7,8-TeCDF 5.6–6.2 0.97
1-Hydroxy-2,4,7,8-tetrachlorodibenzofuran 1-OH-2,4,7,8-TeCDF 240–280 0.02
PHDE-OH
4-Hydroxy-2,4,6-tribromodiphenylether 4-OH-2,4,6-TrBDE 780 to 1,000 0.01
4-Hydroxy-2,3,4,6-tetrabromodiphenylether 4-OH-3,2,4,6-TeBDE 1,000 0.01
4-Hydroxy-2,3,4,5,6-pentabromodiphenylether 4-OH-3,5,2,4,6-PeBDE 200–240 0.03
2-Hydroxy-2,4,4-trichlorodiphenylether 2-OH-4,2,4-TrCDE 850 to 1,000 0.01
BPA
4,4-Isopropylidenediphenol (bisphenol A) BPA 10,000 0.001
3,3,5,5-Tetrachlorobisphenol A 3,5,3,5-TeCBPA 29–53 0.15
3,3,5,5-Tetrabromobisphenol A 3,5,3,5-TeBBPA 12–33 0.30
IC50 values are presented as the range of values from two to four experiments. Relative potencies are calculated as ratio of the IC50 value
of E2 over that of inhibitor.
FIG. 1. Upper part, Core structure of PCDD-OH. Chlorine substitu-
ents are not indicated. Lower part, Inhibition of E2 sulfation by re-
combinant human SULT1E1 by 0.1–1000 nM PCDD-OHs. Reaction
conditions: 1 nM [3H]E2, 0.1g total cytosolic protein/ml, 50M PAPS,
and 30-min incubation. Results are the means of two to four exper-
iments; the coefficient of variation was less than 20%.
FIG. 2. Upper part, Core structure of PCDF-OH. The position of the
hydroxyl group varies between the different PCDF-OHs. Chlorine
substituents are not indicated. Lower part, Inhibition of E2 sulfation
by recombinant human SULT1E1 by 0.01–1000 nM PCDF-OHs. Re-
action conditions: 1 nM [3H]E2, 0.1g total cytosolic protein/ml, 50M
PAPS, and 30-min incubation. Results are the means of two to four
experiments; the coefficient of variation was less than 20%.
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3,5,3,5-TeCBPA and 3,5,3,5-TeBBPA, were relatively po-
tent inhibitors, with mean IC50 values of 40 and 20 nm,
respectively (Fig. 4 and Table 1).
The type of inhibition of E2 sulfation by the different
PHAH-OHs was studied by Lineweaver-Burk analysis (Fig.
5). Depending on the structure, different types of inhibition
were observed. Addition of 2-OH-7,8-DiCDD (Fig. 5A) or
2-OH-7,8-DiCDF (Fig. 5B) changed the slope, but had little
effect on the y-axis intercept of these plots, indicative of
competitive inhibition. However, 2-OH-1,3,7,8-TeCDD (Fig.
5A) and 3-OH-2,4,7,8,9-PeCDF (Fig. 5B) affected both the
slope and the y-axis intercept, and the plots converged at
about the same point on the x-axis, indicating primarily
noncompetitive inhibition by these potent inhibitors. The
Lineweaver-Burk analyses of the effects of BPA and 3,5,3,5-
TeCBPA (Fig. 5C) and of 4-OH-3,5,2,4,6-PeBDE (Fig. 5D)
indicate that these compounds inhibit E2 sulfation primarily
in a noncompetitive manner. The Ki values derived from
these plots are in good agreement with the corresponding
IC50 values for the different inhibitors, amounting to 60 nm
for 2-OH-7,8-DiCDD, 2 nm for 2-OH-1,3,7,8-TeCDD, 270 nm
for 2-OH-7,8-DiCDF, 0.15 nm for 3-OH-2,4,7,8,9-PeCDF, 150
nm for 4-OH-3,5,2,4,6-PeBDE, 14 m for BPA, and 35 nm
for 3,5,3,5-TeCBPA.
Binding of PHAH-OHs to the active site of SULT1E1 is
likely to result in their sulfation, which was tested directly by
incubating 1 m of the various compounds with 0.3 m
[35S]PAPS and SULT1E1. These experiments also included
different PCB-OHs that have previously been shown to in-
hibit E2 sulfation by SULT1E1 (30). Product formation was
analyzed by the method of Foldes and Meek (41), which
involves precipitation of the remaining [35S]PAPS with
BaSO4, presumably leaving the radioactive sulfated products
in solution. The results of this established procedure were
compared with a method developed in our laboratory based
on the separation of labeled PAPS and sulfated products by
HPLC. Figure 6A shows the HPLC analysis of the sulfation
of 2-OH-7,8-DiCDF as a representative example, demonstrat-
ing the clear separation between remaining [35S]PAPS and
35S-labeled sulfated product. Figure 6B shows that there was
reasonable agreement between the results of the two meth-
ods regarding the sulfation of most compounds, although in
several instances the BaSO4 precipitation method signifi-
cantly underestimated the formation of sulfated products in
comparison with HPLC analysis. This was especially the case
with sulfated compounds that were strongly retarded on the
C18 column, suggesting that relatively nonpolar sulfates are
partially lost in the BaSO4 precipitation method.
Table 2 shows the results of the HPLC measurements of
the sulfation of the various PHAH-OHs by SULT1E1 in com-
parison with the sulfation of these compounds by the human
phenol sulfotransferase SULT1A1. We found that most
PHAH-OHs tested in this study were sulfated by SULT1E1
as well as by SULT1A1 (Table 2).
We also studied the inhibition of E2 sulfation by various
PHAH-OHs using human liver cytosol as a source of native
human SULT1E1. Figure 7 compares the effects of different
PHAH-OHs (0.1 or 1 m) on E2 sulfation by SULT1E1 and
FIG. 3. Upper part, Core structure of PBDE-OH. Bromine substitu-
ents are not indicated. Lower part, Inhibition of E2 sulfation by re-
combinant human SULT1E1 by 1–1000 nM PBDE-OHs. Reaction
conditions: 1 nM [3H]E2, 0.1g total cytosolic protein/ml, 50M PAPS,
and 30-min incubation. Results are the means of two to four exper-
iments; the coefficient of variation was less than 20%.
FIG. 4. Upper part, Core structure of BPA derivatives. Halogen sub-
stituents are not indicated. Lower part, Inhibition of E2 sulfation by
recombinant human SULT1E1 by 1–10000 nM BPA or halogenated
BPA. Reaction conditions: 1 nM [3H]E2, 0.1 g total cytosolic protein/
ml, 50M PAPS, and 30-min incubation. Results are the means of two
to four experiments; the coefficient of variation was less than 20%.
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human liver cytosol, showing a strong correlation between
the inhibitions of the recombinant and native enzymes (r 
0.922). In general, human liver enzyme was less potently
inhibited than recombinant human SULT1E1.
Discussion
Structure-activity relationship of SULT1E1 inhibition
by PHAH-OHs
We previously showed that various PCB-OHs potently
inhibit E2 sulfation by human SULT1E1 (30). This finding
suggested that endocrine-disrupting chemicals may act by
increasing the bioavailability of hormones through inhibition
of hormone-conjugating enzymes in target tissues (30, 42). In
this study we tested the effects of other classes of PHAH-OHs
on E2 sulfation by SULT1E1. The results demonstrate that in
all classes of PHAH-OHs tested, those with two adjacent
halogen substituents around the OH group are the most
potent inhibitors of E2 sulfation by SULT1E1, which is in
agreement with the structure-activity relationship found for
SULT1E1 inhibition by single ring halogenated phenols and
hydroxylated PCBs (30). A possible explanation for the in-
crease in potency by adjacent halogen substitutions is the
increased dissociation of the OH group. The potency of in-
hibitors with this substitution pattern decreases in the order
PCDF-OH  PCDD-OH  BPA  PBDE-OH derivatives.
The planar structures of PCDD-OHs and PCDF-OHs vs. the
nonplanar structures of BPAs and PBDE-OHs may play a
role in this, because the patterns for inhibition of SULT1E1
by PCB-OHs suggested preferred binding of coplanar com-
pounds to the enzyme (30). This finding fits with the pri-
marily planar structure of the natural ligand E2. Recently, the
crystal structure of the mouse estrogen sulfotransferase has
been elucidated (43). Mouse and human SULT1E1 show 77%
amino acid sequence identity; both orthologous enzymes
have Km values in the nanomolar range (25, 44). The mod-
eling of hydroxylated PHAHs in E2-binding sites of mouse
SULT1E1 or human SULT1E1, when its crystal structure also
becomes available, should further our understanding of the
structural requirements for inhibition of SULT1E1.
Regarding the varying potencies of the different groups of
(hydroxylated) PHAHs, it should be noted that levels of
exposure are also different for the various PHAHs. The plas-
ticizer BPA is commonly used in the food-packaging indus-
try and in dentistry. Microgram amounts were found in the
liquid from vegetable cans with plastic linings and in the
saliva of patients with dental sealings (45). TBBPA, TCBPA,
FIG. 5. Lineweaver-Burk analysis of the inhibition of the sulfation of 1–20 nM E2 by 0.1 g/ml recombinant human SULT1E1 by 250 nM
2-OH-7,8-DiCDD or 4 nM 2-OH-1,3,7,8-TeCDD (A), by 500 nM 2-OH-7,8-DiCDF or 0.2 nM 3-OH-2,4,7,8,9-PeCDF (B), by 12 M BPA or 60 nM
3,5,3,5-TeCBPA (C), or by 200 nM 4-OH-3,5,2,4,6-PeBDE (D). Results are the mean  SD of two to four experiments. At points where no
error bar is shown the SD is smaller than the symbol.
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and polybrominated diphenylethers are high production
volume chemicals that are widely used in consumer elec-
tronics and many other products as flame retardants; the
production volume of TBBPA in 1995 was higher than 50,000
tons/yr (46). The background exposure of humans to PCDDs
and PCDFs is much lower. Only trace levels (parts per tril-
lion) of PCDDs and PCDFs have been detected in normal
human blood and tissues (47). However, as in our studies
IC50 values for some PCDD-OHs and PCDF-OHs were less
than 1 nm, and 1 nm equals approximately 20 parts per
trillion, the in vitro effects of the most potent PCDD-OHs and
PCDF-OHs were observed at concentrations that may actu-
ally be in the same range that they are present in human
tissues.
Depending on the structure, different types of inhibition
were found with different PHAH-OHs. SULT1E1 is known
to have two substrate-binding sites, the active site as well as
an allosteric site (24, 48). Binding of E2 to the latter site is
thought to be largely responsible for the phenomenon of
substrate inhibition that is observed at increasing E2 con-
centrations. The primarily competitive or noncompetitive
nature by which the different PHAH-OHs inhibit the sul-
fation of E2 by SULT1E1 may thus be explained by their
preferential affinity for the active or the allosteric site,
respectively.
Sulfation of PHAH-OHs by SULT1E1 and SULT1A1
Estrogenic chemicals such as alkylphenols, diethylstilbes-
trol, and BPA have recently been shown to be substrates for
human SULT1A1 (49, 50). In this study we compared the
sulfation of PHAH-OHs by SULT1E1 and SULT1A1. Most of
FIG. 6. A, HPLC analysis of the sulfation of 2-OH-
7,8-DiCDF by SULT1E1 using [35S]PAPS. B, Sulfa-
tion of PHAH-OHs by SULT1E1 measured by the
BaSO4 precipitation method and by HPLC analysis.
Reaction conditions: 1 M substrate, 15 g total cy-
tosolic protein/ml, 0.3 M [35S]PAPS, and 30-min in-
cubation. Results are the mean  SD of triplicate
(BaSO4) or duplicate (HPLC) determinations from a
representative experiment.
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the compounds tested were sulfated by SULT1E1 as well as
by SULT1A1. It should be noted, however, that these incu-
bations had to be performed with a limited PAPS concen-
tration and excess substrate, which is very different from the
conditions used to test the effects of PHAH-OHs on the
sulfation of E2 by SULT1E1. Sulfation of the different PHAH-
OHs was tested at a single substrate concentration of 1 m,
although the IC50 and Ki values for their inhibition of E2
sulfation ranged from less than 1 nm to more than 10 m.
Therefore, the findings presented in Table 2 are not repre-
sentative of the rate of sulfation of the different PHAH-OHs
by SULT1E1 under the conditions where they were tested as
inhibitors of E2 sulfation. Also, in view of the large variation
in saturation of the low Km SULT1E1 and the high Km
SULT1A1 at 1m of the various substrates, the data reported
in Table 2 are not representative of the substrate preferences
of these isoenzymes at lower, more relevant PHAH-OH
concentrations. The in vivo significance of sulfation of hy-
droxylated PHAHs in PHAH metabolism remains to be
established.
Effects of PHAH-OHs on E2 sulfation by human
liver cytosol
The effects of PHAH-OHs on E2 sulfation by SULT1E1 and
by human liver cytosol were highly correlated. However, the
relationship between the rates of E2 sulfation by the different
enzyme preparations was nonlinear. Although SULT1E1 is
the better enzyme for E2 sulfation, with a Km value of ap-
proximately 4 nm, SULT1A1 also catalyzes E2 sulfation, with
a Km value of 2–5 m (51). The potencies of inhibition of
SULT1E1 differ by orders of magnitude from those by which
the different PHAH-OHs inhibit human SULT1A1 activity,
which is characterized by apparent Ki values in the micro-
molar range (33). The nonlinear relationship between the
rates of E2 sulfation by recombinant SULT1E1 and human
liver cytosol in the presence of various PHAH-OHs may be
explained by the presence of SULT1A1 in human liver. How-
ever, at nanomolar concentrations, E2 is predominantly sul-
fated in human liver by SULT1E1 (29), suggesting that the
nonlinear relationship is not due to significant sulfation of E2
in human liver by SULT1A1. A more likely explanation is
suggested by our findings that the PHAH-OHs are sulfated
by SULT1E1 as well as by SULT1A1. Therefore, compared
with recombinant SULT1E1, larger amounts of the PHAH-
OHs will be metabolized in human liver cytosol, decreasing
their inhibitory effects on native SULT1E1. An additional
explanation may be that, compared with recombinant
SULT1E1, human liver cytosol contains more proteins to
which PHAH-OHs bind, diminishing their availability for
native SULT1E1.
Concluding remarks
In this study we have demonstrated that E2 sulfation cat-
alyzed by recombinant human SULT1E1 and that catalyzed
by human liver sulfotransferase are both potently inhib-
TABLE 2. Sulfation of PHAH-OHs by human SULT1E1
and SULT1A1
Compound
Sulfation (% of PAPS added)
SULT1E1 SULT1A1
PCB-OH
4-OH-3,3,4-TrCB 9.9  1.0 19.3  1.8
4-OH-2,3,5,3,4-PeCB 0.6  0.8 0.7  1.0
4-OH-3,2,3,4,5-PeCB 17.6  2.0 6.6  3.1
3-OH-4,5,3,4-TeCB 33.4  3.3 10.5  3.2
2-OH-4,5,3,4-TeCB 19.4  2.8 19.0  4.7
4,4-(OH)2-3,5,3,5-TeCB 1.0  1.1 18.3  2.8
PCDD-OH
2-OH-7,8-DiCDD 70.6  2.7 74.1  10.1
2-OH-3,7,8-TrCDD 22.7  9.5 11.4  1.4
2-OH-1,3,7,8-TeCDD 28.2  3.5 31.7  6.9
PCDF-OH
4-OH-1,3,6,7-TeCDF 6.9  0.3 10.7  1.4
3-OH-2,6,7,8-TeCDF 7.9  1.1 7.3  4.7
3-OH-2,4,7,8-TeCDF 2.5  0.2 3.1  1.1
3-OH-2,4,7,8,9-PeCDF 1.0  0.0 1.0  0.3
2-OH-7,8-DiCDF 82.4  1.7 31.6  4.4
2-OH-6,7,8-TrCDF 81.1  3.1 55.2  8.7
2-OH-1,3,7,8-TeCDF 7.0  1.4 3.3  2.3
1-OH-2,4,7,8-TeCDF 0.0  0.0 24.8  3.4
PHDE-OH
4-OH-2,4,6-TrBDE 2.5  1.4 10.7  0.9
4-OH-3,2,4,6-TeBDE 43.1  6.1 30.4  6.2
4-OH-3,5,2,4,6-PeBDE 13.3  1.9 0.7  0.7
2-OH-4,2,4-TrCDE 89.2  5.1 80.5  7.6
BPA 23.6  2.9 62.0  3.2
3,5,3,5-TeCBPA 7.7  2.5 26.2  1.1
3,5,3,5-TeBBPA 5.8  0.8 15.9  0.7
Reaction conditions: 1 M substrate, 15 (SULT1E1) or 100
(SULT1A1) g total cytosolic protein/ml, 0.3 M [35S]PAPS, and 30-
min incubation. Data are presented as the mean  SD from two to
three experiments.
FIG. 7. Sulfation of E2 by human liver cytosol vs. SULT1E1 in the
presence of different PHAH-OHs. Reaction conditions: 1 nM [3H]E2,
0.1 or 1 M PHAH-OH, 0.1 (SULT1E1) or 10 (human liver) g total
cytosolic protein/ml, 50M PAPS, and 30-min incubation. The PHAH-
OHs tested were the PCDD-OHs and PCDF-OHs listed in Table 1 as
well as 12 different PCB-OHs (compounds 5, 8, 10, 14, 16, 17, 23, 24,
26, 28, 31, and 32 from Ref. 30). Results are expressed as a percentage
of control E2 sulfation in the absence of inhibitor and are presented
as the means of two to four experiments (SULT1E1) or as the means
of triplicate determinations from a representative experiment (hu-
man liver cytosol).
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ited by different classes of PHAH-OHs, with IC50 values
for recombinant SULT1E1 inhibition in the low or even
subnanomolar range. The potent inhibitors 2-OH-3,7,8-
TrCDD, 2-OH-1,3,7,8-TeCDD, 3-OH-2,4,7,8-TeCDF, and
3-OH-2,4,7,8,9-PeCDF, with IC50 values of 34, 4.1, 1.4, and
0.18 nm, respectively, have been identified in mammalian
species (20). The most potent inhibitors have an even higher
affinity for human SULT1E1 than its cognate substrate E2,
which has a Km value of 4 nm for the enzyme (25). Therefore,
we hypothesize that part of the estrogenic activity of PHAHs
is explained by an increase in E2 bioavailability through
inhibition of human SULT1E1 by hydroxylated PHAH me-
tabolites. Such a mechanism for the pseudoestrogenic activ-
ity of PHAH-OHs is particularly relevant for estrogen-
responsive tissues that express SULT1E1, such as the
endometrium, mammary gland, and testis (26–28). The ef-
fects of PHAH-OHs on the regulation of local estrogen levels
in these tissues will depend on a variety of factors, such as
the supply or local generation of the various PHAH metab-
olites, their potency in inhibiting SULT1E1, their rate of in-
activation by SULT1E1 and other isoenzymes such as
SULT1A1, their urinary or biliary excretion rates, and also on
the reversal of the sulfation of E2 and the inhibitors by local
estrogen sulfatase expression (52).
PHAHs are known also to affect the thyroid hormone
system. In laboratory animals, plasma T4 is markedly de-
creased as a result of competitive binding of the hydroxy-
lated metabolites to the plasma carrier transthyretin and
induction of hepatic UDP-glucuronyltransferases by the
PHAHs themselves (53). PHAH-OHs have also been re-
ported to inhibit the in vitro deiodination of thyroid hormone
by the type I iodothyronine deiodinase as well as the sulfa-
tion of the hormone by human SULT1A1 (33). During human
fetal development, sulfation is an important pathway of thy-
roid hormone inactivation (54). We have recently demon-
strated that human SULT1E1 also efficiently catalyzes the
sulfation of iodothyronines, among which are the prohor-
mone T4 and the active hormone T3 (25). Inhibition of
SULT1E1 may thus also have thyroid hormone-disrupting
effects during fetal development. Further studies should de-
termine to what extent estrogen and possibly thyroid hor-
mone levels are disrupted by hydroxylated PHAHs through
inhibition of estrogen sulfotransferase.
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